{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:45:53Z","timestamp":1787535953959,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.adro.2022.100964","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T01:20:40Z","timestamp":1649553640000},"page":"100964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-1130","authenticated-orcid":false,"given":"Sara Beltr\u00e1n","family":"Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Firat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.100964_bib0001","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.bbmt.2017.05.007","article-title":"Allogeneic stem cell transplantation in myelofibrosis","volume":"23","author":"Jain","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PPO.0000000000000169","article-title":"Treatment of myelofibrosis: A moving target","volume":"22","author":"Cerquozzi","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.adro.2022.100964_bib0003","unstructured":"MPN Vo. What every patient with an MPN should know about the spleen voices of MPN: Incyte Corporation 2021. Available at: https:\/\/www.voicesofmpn.com\/mpn-blog\/mpn-patient-splenomegaly.aspx. Accessed September 8, 2021."},{"key":"10.1016\/j.adro.2022.100964_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.adro.2022.100964_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2016.11.016","article-title":"Splenic irradiation for splenomegaly: A systematic review","volume":"53","author":"Zaorsky","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.adro.2022.100964_bib0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11899-020-00598-x","article-title":"Non-pharmacologic management of splenomegaly for patients with myelofibrosis: Is there any role for splenectomy or splenic radiation in 2020?","volume":"15","author":"Sankar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.adro.2022.100964_bib0007","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.adro.2022.100964_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: A report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.adro.2022.100964_bib0009","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2016.02.004","article-title":"Allogeneic transplantation for patients with advanced myelofibrosis: Splenomegaly and high serum LDH are adverse risk factors for successful engraftment","volume":"16","author":"Gergis","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.adro.2022.100964_bib0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jss.2016.06.031","article-title":"Morbidity and mortality after total splenectomy for lymphoid neoplasms","volume":"205","author":"Neuwirth","year":"2016","journal-title":"J Surg Res"},{"key":"10.1016\/j.adro.2022.100964_bib0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1445-2197.1976.tb03189.x","article-title":"Splenectomy: A review of morbidity","volume":"46","author":"Coltheart","year":"1976","journal-title":"Aust N Z J Surg"},{"key":"10.1016\/j.adro.2022.100964_bib0013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/bbmt.1999.v5.pm10392963","article-title":"Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation","volume":"5","author":"Jabro","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1929.x","article-title":"Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"95","author":"Gratwohl","year":"1996","journal-title":"Br J Hematol"},{"key":"10.1016\/j.adro.2022.100964_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"key":"10.1016\/j.adro.2022.100964_bib0016","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1080\/10428194.2017.1321747","article-title":"Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis","volume":"58","author":"Kalman","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.adro.2022.100964_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1620\/tjem.228.295","article-title":"Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly","volume":"228","author":"Ito","year":"2012","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.adro.2022.100964_bib0018","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.6002\/ect.2016.0007","article-title":"Role of allogeneic stem cell transplant in the treatment of primary myelofibrosis","volume":"17","author":"Soyer","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clml.2020.04.015","article-title":"Splenectomy in myelofibrosis: Indications, efficacy, and complications","volume":"20","author":"Malato","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.adro.2022.100964_bib0021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.asjsur.2013.09.002","article-title":"Morbidity- and mortality-related prognostic factors of nontraumatic splenectomies","volume":"37","author":"Gianchandani Moorjani","year":"2014","journal-title":"Asian J Surg"},{"key":"10.1016\/j.adro.2022.100964_bib0022","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0023","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/bmt.2015.295","article-title":"Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms","volume":"51","author":"Hanif","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.adro.2022.100964_bib0024","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MOH.0000000000000381","article-title":"Allogeneic stem-cell transplantation for myelofibrosis","volume":"24","author":"Lavi","year":"2017","journal-title":"Curr Opin Hematol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:41:21Z","timestamp":1762530081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2452109422000719"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.100964","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.100964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100964"}}